Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2017


  • In line with its commitment to transparency, Grifols has disclosed, for the third consecutive year, all payments and other transfers of value to healthcare professionals and health-sector organizations in 33 European countries, including Spain.
  • In 2017, Grifols' transfers of value in Europe dropped by 1% to Euros 11.7 million, compared to Euros 11.8 in 2016
  • Grifols' transfers of value in Spain totaled Euros 5.9 million in 2017 compared to Euros 5.2 million reported in 2016, a 13% increase driven by a higher volume of R+D related transfers of value
  • Transfers of value made in Spain associated with R+D initiatives represent 60% of the group's total transfers in Europe.
  • In 2017, Grifols made transfers of value to 454 healthcare professionals in Spain that amounted to Euros 510,444 (+11% compared to 2016) and 54 health organizations, which totaled Euros 396,145 (-48% in relation to 2016)
  • The Disclosure Code on Industry Interactions with Healthcare Professionals and Healthcare Organizations of the European Federation of Pharmaceutical Industries and Associations (EFPIA) applies specifically to medicines, nonetheless Grifols expands its scope to include transfers unrelated to medications, as well as to the company's three main divisions: Bioscience, Diagnostic and Hospital
  • In addition to Europe, Grifols applies this policy of transparency in the United States as required by the regulatory body (CMS), and also plans to implement it in countries such as Australia and Japan
  • All related information is public and available on the Grifols' corporate website:

Information Published in Accordance With the EFPIA Code of Conduct

Grifols has voluntarily committed to publishing, on its website and on any specific platform required by each country, information on transfers of value to health professionals and health sector organizations corresponding to each reporting period. The company will keep this information publicly available for three years and conserve it for six years.

Depending on the type of activity, the published information includes: donations and subsidies; corporate contributions for events, such as membership fees for healthcare professionals and sponsorship agreements with healthcare organizations, as well as payments to third parties designated to manage the event on their behalf; fees paid for consulting services and projects; travel and accommodation expenses incurred in relation to any of the aforementioned activities; and payments and other transfers of value related to R&D activities.

Specifically, the code of conduct is applied in the following European countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, Norway, Poland, Portugal, Norway, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.